Cortechs.ai | Cortechs.ai announces new capabilities for quantifying FLAIR lesions

Cortechs.ai announces new capabilities for quantifying FLAIR lesions

LesionQuant™, a NeuroQuant® product, enhances our current MRI volumetric image solution to include automated, fast and accurate FLAIR lesion segmentation and quantification.

(SAN DIEGO) Aug. 3, 2016 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce the release of LesionQuant LogoLesionQuant™ for FLAIR lesion identification, segmentation, and quantification. The addition of LesionQuant to the NeuroQuant® family of products marks a notable enhancement to NeuroQuant’s proven volumetric analysis capability by combining information from 2D or 3D FLAIR and 3D T1 MR images and providing lesion and brain structure quantification in a completely automated and optimized easy-to-read report.

Powered by Cortechs.ai’ NeuroQuant and Dynamic Atlas™ technology, LesionQuant delivers a comprehensive and trusted solution for consistent, quality-driven automated MR image analysis. LesionQuant is ready for clinical, research and clinical trial use, provides significant time savings over manual or semi-automatic lesion segmentation and quantification, and is available for a broad age range from 3 to 100 years. LesionQuant delivers further insight to clinicians by providing automated FLAIR lesion segmentation, quantification, and visualization.

“Cortechs.ai’ sole purpose is to enable superior clinical insight by advancing quantitative imaging to improve patient care,” said Guri Stark, Cortechs.ai’ CEO.  “The release of the LesionQuant product extension further solidifies NeuroQuant as the foremost solution in the evaluation of brain disorders. LesionQuant provides clinicians with objective, reliable and consistent quantitative information, aiding in their assessment of gray and white matter lesions, which can be found in a variety of neurological conditions, from Multiple Sclerosis to traumatic brain injury, as well as other neurological diseases.”

LesionQuant features and benefits:

  • Total number and volume of lesions
  • Lesion burden calculation
  • New and enlarging lesion identification and quantification
  • Color-coded lesion visualization
  • Color-coded lesion change visualization
  • Anatomical lesion distribution
  • Quantification of up to 8 relevant brain structures compared to our unique age- and gender-matched normative percentiles

LesionQuant licensing options are now available. For more information on LesionQuant, visit cortechs.ai/lesionquant.

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

More Resources

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

07/28/2025

Longitudinal Assessment of Traumatic Brain Injury Using NeuroQuant®

A case study with Dr. Suzie Bash on NeuroQuant as a reliable, reimbursable, and efficient tool in the evaluation and follow-up of TBI.

07/24/2025

Understanding the Hippocampal Occupancy Score

One of the most frequently asked questions among customers is, “What does the Hippocampal Occupancy Score (HOC) represent within the Dementia Report?”
Scroll to Top